• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    BioAge Labs, Inc. - Common Stock (NQ:BIOA)

    14.33 -0.58 (-3.89%)
    Streaming Delayed Price Updated: 3:27 PM EST, Jan 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 345,921
    Open 14.62
    Bid (Size) 14.25 (200)
    Ask (Size) 14.33 (100)
    Prev. Close 14.91
    Today's Range 14.14 - 15.08
    52wk Range 2.880 - 16.43
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tuesday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole ↗
    Don't be too quick to jump on this biotech bandwagon. 
    Via The Motley Fool

    Performance

    YTD
    +11.7%
    +11.7%
    1 Month
    +21.1%
    +21.1%
    3 Month
    +152.7%
    +152.7%
    6 Month
    +209.5%
    +209.5%
    1 Year
    +167.4%
    +167.4%

    More News

    Read More
    News headline image
    BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs to Present at Jefferies Global Healthcare Conference in London
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs Inc (NASDAQ:BIOA) Reports Q3 2025 Earnings with Significant Revenue Beat ↗
    Via Chartmill
    News headline image
    BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy ↗
    Via The Motley Fool
    News headline image
    Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? ↗
    Via The Motley Fool
    News headline image
    BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? ↗
    Via The Motley Fool
    News headline image
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Which stocks are moving on Thursday? ↗
    Via Chartmill
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
    Via Benzinga
    News headline image
    BIOAGE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    BioAge Labs to Present at Upcoming Investor Conferences
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs (BIOA) Q2 Revenue Hits $2.4M ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
    From BioAge Labs, Inc.
    Via GlobeNewswire
    News headline image
    BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank
    From BioAge Labs, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is BioAge Labs, Inc. - Common Stock publicly traded?
    Yes, BioAge Labs, Inc. - Common Stock is publicly traded.
    What exchange does BioAge Labs, Inc. - Common Stock trade on?
    BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for BioAge Labs, Inc. - Common Stock?
    The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market
    What is the current price of BioAge Labs, Inc. - Common Stock?
    The current price of BioAge Labs, Inc. - Common Stock is 14.33
    When was BioAge Labs, Inc. - Common Stock last traded?
    The last trade of BioAge Labs, Inc. - Common Stock was at 01/08/26 03:27 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.